Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Biological staging of individuals with Alzheimer’s disease (AD) may improve diagnostic and prognostic workup of dementia in clinical practice and the design of clinical trials. In this study, we used the Subtype and Stage Inference (SuStaIn) algorithm to establish a robust biological staging model for AD using cerebrospinal fluid (CSF) biomarkers. Our analysis involved 426 participants from BioFINDER-2 and was validated in 222 participants from the Knight Alzheimer Disease Research Center cohort. SuStaIn identified a singular biomarker sequence and revealed that five CSF biomarkers effectively constituted a reliable staging model (ordered: Aβ42/40, pT217/T217, pT205/T205, MTBR-tau243 and non-phosphorylated mid-region tau). The CSF stages (0–5) demonstrated a correlation with increased abnormalities in other AD-related biomarkers, such as Aβ-PET and tau-PET, and aligned with longitudinal biomarker changes reflective of AD progression. Higher CSF stages at baseline were associated with an elevated hazard ratio of clinical decline. This study highlights a common molecular pathway underlying AD pathophysiology across all patients, suggesting that a single CSF collection can accurately indicate the presence of AD pathologies and characterize the stage of disease progression. The proposed staging model has implications for enhancing diagnostic and prognostic assessments in both clinical practice and the design of clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Hosmer, D. W., Lemeshow, S., & Sturdivant, R. X. (2013) · Wiley Series in Probability and Statistics · doi:10.1002/9781118548387 · Cited by 13,861
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationNichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“Notably, this sequence of events is in line with previous literature 54,55 and demonstrates that late-onset sporadic AD molecular pathway matches the same sequence of events as autosomal dominant AD 29 .”
ResultSelf-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · cited 4×
“…status with a single CSF collection may be very useful to select the optimal participants for a clinical trial, such as has been done in the donanemab trial (NCT03367403) 11 , without the need of acquiring both an amyloid-PET and a tau-PET scan to determine if a patient is eligible for treatment.”
BackgroundMethodInfluentialSelf-citationVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 9×
“A total of 426 participants from the Swedish BioFINDER-2 study (NCT03174938) 19 with complete CSF data were included in the present study.”
BackgroundMethodInfluentialSelf-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348 · cited 1×
“SUVR values were transformed to Centiloids 74 to allow direct comparison between tracers using previously validated transformations 75 .”
MethodSelf-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationAugustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972 · cited 6×
“Model development was done with SuStaIn 41 using cross-sectional data of amyloid-positive participants based on CSF Aβ42/40 levels.”
BackgroundInfluentialMorris, J. C., Weintraub, S., Chui, H. C., Cummings, J., DeCarli, C., Ferris, S., Foster, N. L., Galasko, D., Graff-Radford, N., Peskind, E. R., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213865.09806.92 · Cited by 950
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741 · cited 4×
“SuStaIn is an optimal approach to answer this question as it allows the modeling of different trajectories, if existent for subgroups of the whole sample, using cross-sectional data 41 , as has been successfully applied to imaging biomarkers 35,36,46 .”
BackgroundMethodResultInfluentialSelf-citationTau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · cited 1×
“12–17), p-tau217 (refs.”
Self-citationPlasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688 · cited 2×
“Previous studies already suggested that changes in the levels of tau fragments phosphorylated at different sites may be linked mechanistically and could be associated with disease stages 47–51 .”
Backgroundthe Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationThijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00214-3 · Cited by 607
Self-citationYoung, A. L., Marinescu, R. V., Oxtoby, N. P., Bocchetta, M., Yong, K., Firth, N. C., Cash, D. M., Thomas, D. L., Dick, K. M., Cardoso, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05892-0 · Cited by 596
Self-citationTau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · cited 1×
“These results support the use of our staging model as an enrichment technique for clinical trials 60 .”
MethodSelf-citationIn vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
Performance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465 · cited 2×
“12,13,15,18,19) and p-tau231 (refs.”
BackgroundIn vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440 · cited 1×
“The progression of Aβ or tau pathology across the brain has been previously used to stage participants across the AD continuum 33–38 .”
MethodSelf-citationAshton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436 · cited 1×
“These biomarkers have shown their utility in improving the diagnostic workup of AD and the prediction of disease progression 12,13,19,26,27 .”
BackgroundSelf-citationBrain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · cited 1×
“For instance, rates of Aβ accumulation across CSF stages showed the previously reported inverted U shape 3,58 , with participants at CSF stage 2 (pT217/T217) exhibiting the highest rates of change.”
BackgroundSuárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401
Self-citationPalmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400
Self-citationLongitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L., et al. (2020) · Brain · doi:10.1093/brain/awaa286 · Cited by 368
Self-citationMattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359 · cited 1×
“…of soluble amyloid species (that is, low Aβ42/40) may drive hyper-phosphorylation of tau in early phosphorylation site (pT217/T217), as previously suggested by human and animal data 52,53 , which would subsequently be followed by hyper-phosphorylation in later site (pT205/T205) and eventually”
BackgroundSelf-citationMilà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353 · cited 3×
“In our model, CSF stages could be related to main molecular changes and clinical tipping points in the course of the disease, including abnormal levels of deposited Aβ (CSF stage 2: pT217/T217) 19,20,23,25,26,28,29,32 and tau (CSF stage 3: pT205/T205) (refs.”
BackgroundSelf-citationOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · cited 2×
“Key biomarkers may help to improve patient diagnosis, management and prognosis 5–8 .”
BackgroundSelf-citationMattsson-Carlgren, N., Salvadó, G., Ashton, N. J., Tideman, P., Stomrud, E., Zetterberg, H., Ossenkoppele, R., Betthauser, T. J., Cody, K. A., Jonaitis, E. M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5272 · Cited by 309
Self-citationA data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114022 · Cited by 261 · cited 1×
“…of soluble amyloid species (that is, low Aβ42/40) may drive hyper-phosphorylation of tau in early phosphorylation site (pT217/T217), as previously suggested by human and animal data 52,53 , which would subsequently be followed by hyper-phosphorylation in later site (pT205/T205) and eventually”
BackgroundSelf-citationCSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Self-citationStaging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237 · cited 2×
“Subsequently, we looked at the accuracy of our CSF staging model for predicting Aβ (A) and tau (T) status, as defined by PET 34 (Fig.”
MethodResultSelf-citationLuna-Muñoz, J., Chávez-Macías, L., García-Sierra, F., & Mena, R. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12410 · Cited by 233
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205 · cited 3×
“In our model, CSF stages could be related to main molecular changes and clinical tipping points in the course of the disease, including abnormal levels of deposited Aβ (CSF stage 2: pT217/T217) 19,20,23,25,26,28,29,32 and tau (CSF stage 3: pT205/T205) (refs.”
BackgroundSelf-citationCerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
Ashton, N. J., Benedet, A. L., Pascoal, T. A., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Mathotaarachchi, S., Therriault, J., Savard, M., Chamoun, M., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103836 · Cited by 184 · cited 2×
“15,20–22) or the phosphorylation occupancies (defined as the ratio between the phosphorylated and non-phosphorylated mid region tau (np-tau) fragments) have been studied in depth and have shown strong associations with Aβ pathology and moderate associations with tau (as measured by both positron…”
BackgroundCSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180
Self-citationBarthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153 · cited 5×
“28,29,32), early cognitive impairment (CSF stage 4: MTBR-tau243) (ref.”
BackgroundMethodInfluentialSelf-citationBiomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4654 · Cited by 149
Self-citationAlzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation
Stefanoska, K., Gajwani, M., Tan, A. R. P., Ahel, H. I., Asih, P. R., Volkerling, A., Poljak, A., & Ittner, A. (2022) · Science Advances · doi:10.1126/sciadv.abl8809 · Cited by 128 · cited 2×
“Previous studies already suggested that changes in the levels of tau fragments phosphorylated at different sites may be linked mechanistically and could be associated with disease stages 47–51 .”
BackgroundSalvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46
Self-citationProteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11 · cited 1×
“In Knight ADRC, CSF Aβ42/40 levels were measured as described previously 28,69 .”
MethodSelf-citationChen, C. D., Ponisio, M. R., Lang, J. A., Flores, S., Schindler, S. E., Fagan, A. M., Morris, J. C., & Benzinger, T. L. S. (2023) · Journal of Alzheimer’s Disease · doi:10.3233/jad-230032 · Cited by 10
Self-citation
Cited by
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
(2024) · doi:10.1002/alz.14315 · Cited by 199
“46,54 57 AD biomarker testing is now of greater importance in clinical practice to determine if patients may be candidates for new FDA-approved AD-specific treatments.”
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Self-citationHu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Self-citation
Metadata
- Authors
- Salvadó, G., Horie, K., Barthélemy, N. R., Vogel, J. W., Pichet Binette, A., Chen, C. D., Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., Palmqvist, S., Stomrud, E., Janelidze, S., Ossenkoppele, R., Schindler, S. E., Bateman, R. J., & Hansson, O.
- Venue
- Nature Aging
- Published
- 2024-03-21
- Volume
- 4
- Issue
- 5
- Pages
- 694-708
- ISSN
- 2662-8465 (ISSN-L)
- OpenAlex
- W4393043443
- Cited by
- 113
- References
- 55
- FWCI
- 30.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.